Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Nephron Pharmaceuticals Corporation
Lobbying Relationship
Bills mentioned
H.R.965: CREATES Act of 2019
Sponsor: David Cicilline (D-R.I.)
H.R.2375: Preserve Access to Affordable Generics and Biosimilars Act
Sponsor: Jerrold Nadler (D-N.Y.)
H.R.2374: Stop STALLING Act
Sponsor: Hakeem Jeffries (D-N.Y.)
H.R.2376: Prescription Pricing for the People Act of 2019
Sponsor: Doug Collins (R-Ga.)
H.R.1503: Orange Book Transparency Act of 2020
Sponsor: Robin Kelly (D-Ill.)
H.R.1520: Further Extension of Continuing Appropriations Act, 2021
Sponsor: Anna G. Eshoo (D-Calif.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Alex Vogel | Chief Counsel, Senate Majority Leader Bill Frist Former Chief Counsel, Senate Majority Leader Bill Frist |
| Brian Johnson | Director of Federal Affairs, American Petroleum Institute Former Director of Federal Affairs at the American Petroleum Institute |
| Jennifer Mallard | Health Policy Advisor to Chief Deputy Whip and House Energy and Commerce Committee Member Rick Lazio (R-NY) |
| Samir Kapadia | n/a |
| Gabrielle Smith | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate